Biohaven’s drug for genetic neurological disease fails late-stage study Reuters May 25, 2022 The main goal in the Biohaven study measured the change in severity of symptoms among patients who took the drug, troriluzole,…
Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine EP News Bureau Feb 15, 2022 This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in…
